Clinical trials: Cystic Fibrosis Pulmonary Exacerbation
Cystic Fibrosis (CF), Bronchiectasis Adult
Novel Sensors and Artificial Intelligence for Detection of Acute Pulmonary Exacerbations in Cystic Fibrosis and Bronchiectasis
The goal of this observational study is to learn about new sensors that measure changes in the body that happen during a chest infection, such as breathing rate and heart rate.
- Trial name
- NOVEL (NCT07289100)
- Testing
- Non-Interventional Study
- Where
- United Kingdom
- Volunteers
- 50 people
- Sponsor
- Papworth Hospital NHS Foundation Trust
Cystic Fibrosis (CF), Pulmonary Exacerbation
Pharmacokinetics of Antibiotics in Patients With Cystic Fibrosis Trated With Elexacaftor/Tezacaftor/Ivacaftor (ETI)
Cystic fibrosis (CF) is associated with major pharmacokinetic and pharmacodynamic alterations affecting antibiotic exposure, including changes in absorption, distribution, metabolism, and elimination.
- Conditions
- Cystic Fibrosis (CF), Pulmonary Exacerbation, Respiratory Infection Bacterial
- Trial name
- PKCF (NCT07629986)
- Testing
- No intervention assigned
- Where
- France
- Volunteers
- 30 people
- Sponsor
- Fondation Ildys
Bronchiectasis
Ciprofloxacin Dry Powder for Inhalation in Non-cystic Fibrosis Bronchiectasis (Non-CF BE)
The purpose of this study is to evaluate if the time to first pulmonary exacerbation of bronchiectasis or its frequency can be prolonged by inhalation of ciprofloxacin for 28 days every other 28 days or for 14 days every other 14…
- Trial name
- RESPIRE 1 (NCT01764841)
- Testing
- Ciprofloxacin DPI (BAYQ3939)
- Where
- 151 sites in United States, Argentina and 12 more
- Volunteers
- 416 people
- Sponsor
- Bayer
Cystic Fibrosis
Study of Long-term Treatment With Hypertonic Saline in Patients With Cystic Fibrosis
A phase IV clinical trial, multicentric (3 Hospitals in Madrid) controlled, prospective, open and randomized of long-term treatment with hypertonic saline in cystic fibrosis patients.
- Trial name
- NCT01377792
- Testing
- Hypertonic saline
- Where
- Spain
- Volunteers
- 71 people
- Sponsor
- Adelaida Lamas Ferreiro
Bronchiectasis
Functional Respiratory Imaging in Bronchiectasis
Four-week prospective single centre exploratory study in adults with bronchiectasis suffering a pulmonary exacerbation (defined as a change in one or more of the following: cough; sputum amount; sputum colour; breathlessness…
- Trial name
- FRIBE (NCT03818646)
- Testing
- Functional Respiratory Imaging
- Where
- United Kingdom
- Volunteers
- 10 people
- Sponsor
- Papworth Hospital NHS Foundation Trust
Cystic Fibrosis
18FDG-PET Imaging to Detect Changes in Airways Inflammation in Cystic Fibrosis Patients
The purpose of this study is to determine if 18Fluorodeoxyglucose (FDG) Positron Emission Tomography (PET) imaging can detect changes in airways inflammation in Cystic Fibrosis (CF) patients after treatment for a pulmonary…
- Trial name
- NCT00684346
- Testing
- 18-FDG
- Where
- Canada
- Volunteers
- 20 people
- Sponsor
- The Hospital for Sick Children
Lung Diseases, Pulmonary Disease
A Study of the Safety and Tolerability of Inhaled SNSP113 in Healthy Subjects and Subjects With Stable Cystic Fibrosis
Although Cystic Fibrosis is a complex genetic disease affecting many organs, lung disease is the primary cause of mortality. The objective of this study is to determine the safety and tolerability of SNSP113 in healthy subjects…
- Conditions
- Lung Diseases, Pulmonary Disease, Cystic Fibrosis, Cystic Fibrosis Lung
- Trial name
- NCT03309358
- Testing
- Inhaled SNSP113
- Where
- 2 sites in United Kingdom
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Synspira, Inc.
Cystic Fibrosis, Cystic Fibrosis Pulmonary Exacerbation
Standardizing Treatments for Pulmonary Exacerbations - Aminoglycoside Study
The purpose of this study is to look at pulmonary exacerbations in people with cystic fibrosis (CF) that need to be treated with antibiotics given through a tube inserted into a vein (intravenous or IV).
- Trial name
- STOP360AG (NCT05548283)
- Testing
- Beta-lactam antibiotic, Aminoglycoside
- Where
- 60 sites in United States, Canada
- Volunteers
- 730 people
- Sponsor
- Chris Goss
Cystic Fibrosis
A Study of the Dosing, Efficacy, and Safety of Oral Cysteamine in Adult Patients With Cystic Fibrosis Exacerbations
This study investigates the use of cysteamine in the treatment of adults with Cystic Fibrosis who are experiencing an exacerbation of CF-associated lung disease.
- Trial name
- CARE-CF1 (NCT03000348)
- Testing
- Cysteamine
- Where
- 17 sites in United States, Italy and 1 more
- Volunteers
- 91 people
- Sponsor
- NovaBiotics Ltd.
Cystic Fibrosis
Cystic Fibrosis Foundation (CFF) Biomarkers of Exacerbation
Clinical and translational research in cystic fibrosis (CF) is hampered by a lack of biomarkers that can be used to identify promising new therapies.
- Trial name
- NCT00788359
- Where
- 5 sites in United States
- Volunteers
- 123 people
- Sponsor
- University of Colorado, Denver
Cystic Fibrosis
Outpatient Antibiotic Treatment for a Cystic Fibrosis Pulmonary Exacerbation
This study plans to learn more about the effect of oral antibiotics for an outpatient pulmonary exacerbation (respiratory illness) on sputum (mucus) bacterial infections, lung function, airway inflammation and quality of life.
- Trial name
- NCT02480270
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- University of Colorado, Denver
Cystic Fibrosis
Clinical Utility of the 1-minute Sit to Stand Test as a Measure of Submaximal Exercise Tolerance in Patients With Cystic Fibrosis During Acute Pulmonary Exacerbation
The aim of this study is to assess whether the 1 minute Sit to Stand (STS) test can be used as a measure of submaximal endurance during a pulmonary exacerbation of Cystic Fibrosis (CF) for patients in the acute care setting.
- Trial name
- NCT04058548
- Testing
- Sit to stand test
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- Boston Children's Hospital
Bronchiectasis
Ciprofloxacin Dry Powder for Inhalation (DPI) in Non-cystic Fibrosis Bronchiectasis (Non-CF BE)
The purpose of this study is to evaluate if the time to first pulmonary exacerbation of bronchiectasis or its frequency can be prolonged by inhalation of ciprofloxacin for 28 days every other 28 days or for 14 days every other 14…
- Trial name
- RESPIRE 2 (NCT02106832)
- Testing
- Ciprofloxacin (BAYQ3939) dry powder for inhalation
- Where
- 207 sites in United States, Argentina and 23 more
- Volunteers
- 521 people
- Sponsor
- Bayer
Alzheimer Disease, Late Onset, Stroke
Explore the Sharing Model Intervene to Improve the Knowledge, Attitudes, Service Intentions and Service Start-up Effects of the Eight Major Non-cancer Disease End-stage Caregivers on Well-being and Palliative Care
Since September 1st, 2009, Taiwan has begun to pay attention to the care of patients with organ failure, dementia and the elderly, and brought eight of non-cancer terminal patients into health insurance subsidies to implement the…
- Conditions
- Alzheimer Disease, Late Onset, Stroke, Heart Failure, Pulmonary Disease, Chronic Obstructive
- Trial name
- NCT05407272
- Testing
- Health Education Manual, manual
- Where
- Taiwan
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Wen-Shiou Pan
Cystic Fibrosis, Cystic Fibrosis Pulmonary Exacerbation
Study to Determine the Efficacy&Safety of ARV-1801(ACG-701) for the Treatment of Cystic Fibrosis Pulmonary Exacerbations
This study will evaluate the efficacy and safety of an oral ARV-1801(ACG-701) plus optimized background therapy (OBT) compared to oral placebo plus OBT, each administered for 14 days, in the treatment of participants with Cystic…
- Trial name
- REPRIEVE (NCT05641298)
- Testing
- Sodium Fusidate
- Where
- 25 sites in United States
- Sponsor
- Aceragen
Cystic Fibrosis, Respiratory Failure
Non Invasive Ventilation for Acute Exacerbations in Adult CF
Cystic Fibrosis (CF) is a life limiting illness. Median predicted UK survival is 41.4 years (UK CF Registry 2011). The commonest cause of death is respiratory failure.
- Trial name
- NIVinCF (NCT02234401)
- Testing
- Bi level pressure support, Standard Care
- Where
- United Kingdom
- Volunteers
- 16 people
- Sponsor
- Manchester Metropolitan University
Cystic Fibrosis
Biomarkers of Iron Homeostasis and Responses to Cystic Fibrosis Pulmonary Exacerbation (CFPE) Treatment
The goal of this study is to identify chemical compounds in the blood and sputum (i.e., biomarkers) that are associated with objective measurements of health status in patients with cystic fibrosis (CF).
- Trial name
- NCT02188758
- Testing
- Adults - CFPE Treatment
- Where
- 2 sites in United States
- Volunteers
- 20 people
- Sponsor
- Dartmouth-Hitchcock Medical Center
Cystic Fibrosis
Continuous Infusion Piperacillin-tazobactam for the Treatment of Cystic Fibrosis
Cystic fibrosis is an inherited disorder leading to chronic pulmonary inflammation and infection. A majority of people with cystic fibrosis have large quantities of bacteria residing in their lungs.
- Trial name
- PIPE-CF (NCT01694069)
- Testing
- Piperacillin-tazobactam combination product
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- West Virginia University
Cystic Fibrosis
PEP and O-PEP Device for Nebulization in Cystic Fibrosis
Physiotherapy is an essential element in the comprehensive treatment of patients with cystic fibrosis. In symptomatic individuals, from a respiratory system perspective, it should be performed regularly, as it directly…
- Trial name
- NCT06964074
- Testing
- Nebulization with OPEP device, Nebulization with PEP device, Nebulization with Pari LC Sprint
- Where
- 2 sites in Poland
- Volunteers
- 70 people
- Sponsor
- National Institute for Tuberculosis and Lung Diseases, Poland
Cystic Fibrosis
Long Term Administration of Inhaled Dry Powder Mannitol In Cystic Fibrosis - A Safety and Efficacy Study
The purpose of this study is to determine the efficacy and safety of chronic treatment with inhaled dry powder mannitol in subjects with cystic fibrosis.
- Trial name
- NCT00446680
- Testing
- Mannitol
- Where
- 29 sites in Australia, Ireland and 1 more
- Volunteers
- 340 people
- Sponsor
- Syntara